$1.28
2.40% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US98943L1070
Symbol
ZNTL
Sector
Industry

Zentalis Pharmaceuticals Inc Stock price

$1.28
-0.08 5.88% 1M
-1.85 59.11% 6M
-1.75 57.76% YTD
-10.51 89.14% 1Y
-21.13 94.29% 3Y
-39.79 96.88% 5Y
-21.92 94.48% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.03 2.40%
ISIN
US98943L1070
Symbol
ZNTL
Sector
Industry

Key metrics

Market capitalization $92.10m
Enterprise Value $-201.70m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.33
EV/Sales (TTM) EV/Sales -7.51
P/S ratio (TTM) P/S ratio 3.43
P/B ratio (TTM) P/B ratio 0.31
Revenue growth (TTM) Revenue growth -33.76%
Revenue (TTM) Revenue $26.87m
EBIT (operating result TTM) EBIT $-199.37m
Free Cash Flow (TTM) Free Cash Flow $-151.70m
Cash position $332.45m
EPS (TTM) EPS $-3.15
P/E forward negative
Short interest 10.11%
Show more

Is Zentalis Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Zentalis Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:

4x Buy
44%
5x Hold
56%

Analyst Opinions

9 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:

Buy
44%
Hold
56%

Financial data from Zentalis Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
27 27
34% 34%
100%
- Direct Costs 1.23 1.23
9% 9%
5%
26 26
35% 35%
95%
- Selling and Administrative Expenses 80 80
30% 30%
296%
- Research and Development Expense 144 144
24% 24%
537%
-198 -198
7% 7%
-737%
- Depreciation and Amortization 1.23 1.23
9% 9%
5%
EBIT (Operating Income) EBIT -199 -199
7% 7%
-742%
Net Profit -224 -224
2% 2%
-834%

In millions USD.

Don't miss a Thing! We will send you all news about Zentalis Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zentalis Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
6 days ago
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zenta...
Neutral
GlobeNewsWire
19 days ago
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on May 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options t...
Neutral
GlobeNewsWire
23 days ago
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and b...
More Zentalis Pharmaceuticals Inc News

Company Profile

Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.

Head office United States
CEO Julia Eastland
Employees 166
Founded 2014
Website www.zentalis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today